Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: axial who wrote (8831)	2/17/2002 6:11:28 PM
From: Montana Wildhack	Respond to of 14101

Lifted this from Emid on SH referring to a posting on the Yahoo JNJ board. Can't speak to the validity but an interesting perspective from a JNJ view. Yahoo! Message Boards - Message Matches (1 - 20 of 22) Business & Finance > Investments > Sectors > Healthcare > Major Drugs > JNJ Re: JnJ's pipeline: DMX up 30% - I don't know about JNJ's interest in buying Dimethaid Research, the small Canadian pharma that has developed Pennsaid Lotion for Osteo. Arthritis, with McNeil/JNJ as the expected US merketing partner. I do know that this partnership will contribute to the JNJ bottom line significantly, but a better way to leverage this new rival to the COX-2s might be to buy shares in the Canadian pharma itself (DMX on TSE). Either way, it is great to have in the works a safe alternative the COX-2 killers. Cheers - by: erieshore385 Re: In the Pipeline - Gr4Style wrote: " I do know them, and wish to know what is your knowledge about their stanstill agreement with the JNJ sub.?" Its a hush hush agreement, the CEO when confronted only says the McNeil is still solidly there and cannot comment further. DMX submitted their FDA NDS April 1999. Then one month later they sign the standstill agreement with JnJ for a measely $2million USD upfront. Just mere JnJ spare change from their dash board. Its probably a milestone driven agreement. I understand with milestones more upfront money gets deposited into DMX bank account. At this point in time, it looks like JnJ got the better of the deal and a great deal at that. Its almost 3 years since. Just about the right time frame. I bet 9/11 attack added to the time frame. Here's the clip from a DMX annual report. STANDSTILL AGREEMENT "In May 1999, DII entered into an agreement with McNeil Consumer Healthcare, a wholly owned subsidiary of Johnson & Johnson, with respect to an exclusive negotiat - by: excambian Re: In the Pipeline - DMX on Toronto TSE has a market cap of $209 million dollars Canadian. This translates in to $130 million USD. Based on a confirmed FDA plant inspection that took place about Dec 18, 2001, adding in the christmas holidays, an FDA inspection report should be hitting their desk any time now. Any of three possibilities (a) plant is approval (b) deficiencies = a delay of a few months (c) total rejection Total rejection gotta be low chance. The are approved and selling in the UK. I would assume JnJ McNeil would be helping is the filing and also auditing the plant before FDA inspection. In any case, (a) FDA approvable in a month or (b) FDA approvable in 6 months. - by: excambian Re: In the Pipeline - Exambian, are you from Can or US. You sure know alot about this company Dimethaid Research. I do know them, and wish to know what is your knowledge about their stanstill agreement with the JNJ sub.? Yes I do agree the mkt cap is low for DMX, but then after their FDA approval of Penssaid and the finalization of the mcneil agreement for JNJ to distribute the Penssaid product in the US, this may turn out to have been a fire sale. - by: gr4style Re: In the Pipeline - GR4Stlye I'm a cyber cowboy doing my share and paying back for all 'good' tips I hacve picked up on Yahoo, Fool, and SI over the years. Sometimes more profitable to dig out the little companies the BIG Gorilla pharms latched onto. Seriously, I follow other major Pharmas closer than JnJ, but would like feedback for how JnJ normally behaves with juniors in their pipeline. ""Where did you get this kind of detailed information about this comapany and their dealings with JnJ?"" All public information!! "May 1999 Dimethaid International Inc. and McNeil Consumer Healthcare, a wholly owned subsidiary of Johnson & Johnson announced a standstill agreement for the US distribution rights, for which US $2.0 million was received. Negotiations continue for a comprehensive agreement. " dimethaid.com Other links 1. Good summary of DMX at their website, Presidents year end 2001 message to shareholders. Beware this message change from time to time: dimethai - by: excambian Re: In the Pipeline - Excambian: """JnJ has a lock down, hush hush agreement in place with a Canadian company call Dimethaid for the US distribution rights for a product called Pennsaid. FDA approval is around the corner for Pennsaid, speculated to happen around March 2002. Symbol is DMX on the TSE. Pennsaid is a topical lotion which combines Dimethaid's patented transdermal delivery technology with Diclofenac, a non-steroidal anti-inflamatory drug (NSAID). It is used for treatment of pain associated with arthritis. From clinicals incliding Phase III, no side effects! The drugs label should be way shorter than Merck and Pharmacia's COX II block busters and JnJ foe in the pain market place. DMX's board of director include: Percy Skuy Former President Ortho-McNeil Inc. (Johnson & Johnson) An that's not all, there's Stephen Wilgar Former President of Warner Lambert Inc. (Pfizer)""" Where did you get this kind of detailed information about this comapany and their dealings with JnJ? This drug Penssaid, is suppos - by: gr4style